Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

The REST (Replacing Steroids in the transplant ineligible) study. Ended

2023-510194-34-00 Multiple myeloma 4 2021-06-18
Chemotherapy-Free pCR-Guided Strategy with subcutaneous trastuzumabpertuzumab and T-DM1 in HER2-positive early breast cancer (PHERGAIN-2) Ended

2023-508738-32-00 Previously untreated and histologically confirmed HER2- 4 2021-06-16
PSMAfore: A phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of androgen receptor-directed therap… Ended

2023-507772-50-00 PSMA-positive metastatic castration-resistant prostate 5 2021-06-16
Phase Ib/III Study of Capivasertib + CDK4/6 Inhibitors + Fulvestrant as Treatment for Advanced/Metastatic HR+/HER2-Breast Cancer (CAPItello-… Ended

2023-504997-39-00 Hormone Receptor-Positive and Human Epidermal Growth Fa 5 2021-06-14
A study to investigate the efficacy and safety of trastuzumab deruxtecan in patients With or Without Brain Metastasis Who Have Previously-Tr… Ended

2024-510588-53-00 Treatment of patients with HER2-positive breast cancer 11 2021-06-10
A Study of the Efficacy and Safety of Galinpepimut-S (GPS) for the Treatment of Acute Myeloid Leukemia Compared to Investigator's Choice of … Ended

2024-516405-23-00 Acute myeloid leukemia (AML) in second or later complet 5 2021-06-08
A Phase 3 study of Tafasitamab plus Lenalidomide in addition to Rituximab, versus Lenalidomide plus Rituximab in patients With Relapsed/Refr… Ended

2023-504684-16-00 follicular lymphoma (FL) and marginal zone lymphoma (MZ 5 2021-06-05
A Phase 1b/2 Study of BMS-986158 Monotherapy and Combination with either Ruxolitinib or Fedratinib in Intermediate or High Risk Myelofibrosi… Ended

2023-509635-89-00 DIPSS-Intermediate or High Risk Myelofibrosis 9 2021-06-01
Trastuzumab deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab as First-line Treatment in HER2-positive… Ended

2023-505249-24-00 HER2-positive metastatic breast cancer 5 2021-05-27
Comparing Paclitaxel-Carboplatin-Oregovomab versus Paclitaxel-Carboplatin-Placebo in Patients with Advanced Ovarian Cancer Ended

2024-519218-30-00 Advanced epithelial ovarian, fallopian tube or peritone 5 2021-05-26
A Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy in Participants with St… Ended

2023-508372-10-00 Non small Cell Lung cancer 4 2021-05-19
Isatuximab in combination with belantamab mafodotin and dexamethasone in RRMM. Ended

2024-514989-40-00 Cancer 9 2021-05-17
A Randomised, Double-Blind, Phase III Study of AZD9833 plus Palbociclib versus Anastrozole plus Palbociclib in Patients with ER-Positive HER… Ended

2023-503995-26-00 Estrogen Receptor-Positive, HER2-Negative Advanced Brea 5 2021-05-11
An Open-label, Randomized Phase 3 Study of Immune and Targeted Combination Therapies, as First-line Treatment in Participants with Advanced … Ended

2022-502122-41-00 Clear cell renal cancer 5 2021-05-11
DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer Ended

2023-509865-19-00 Advanced or Metastatic Non-small Cell Lung Cancer (NSCL 5 2021-04-30
Phase 3 Trial of Perioperative EV and Pembro vs. Chemo in Cis-E MIBC Ended

2023-505615-21-00 Muscle Invasive Bladder Cancer 5 2021-04-28
Study of efficacy and safety of LXH254 combinations in patients with previously treated unresectable or metastatic melanoma Ended

2024-511934-11-00 Previously treated unresectable or metastatic BRAFV600 4 2021-04-27
Trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to standard therapy versus standard therapy in patients… Ended

2022-500237-92-00 Newly-diagnosed high-intermediate and high-risk diffuse 5 2021-04-23
A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Alone and in Combination With Ruxolitinib in Participants Wit… Ended

2023-507274-40-00 Myelofibrosis 3 2021-04-22
Study to evaluate safety and dosimetry of Lutathera in adolescent patients with GEP-NETs and PPGLs. Ended

2023-507444-37-00 somatostatin receptor positive gastroenteropancreatic n 4 2021-04-21
To test the safety, efficacy and tolerability of a drug called trametinib and determine the duration of treatment in children with histiocyt… Ended

2024-515896-37-00 histiocytic cell proliferation 4 2021-04-20
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (M… Ended

2023-507188-21-00 Muscle-Invasive Urothelial Carcinoma (MIBC) of the Blad 5 2021-04-20
Clinical trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer f… Ended

2023-507961-24-00 High-Risk HER2-Positive Breast Cancer 5 2021-04-19
Phase 3 Study of Belzutifan in Combination With Lenvatinib Versus Cabozantinib for Treatment of RCC Ended

2024-510620-39-00 Advanced RCC with clear cell component 5 2021-04-19